Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
ABEV3 heads into its October 28 earnings date with the analyst community having shifted firmly cautious, even as the lending market shows no sign of short sellers pressing the trade.
The Street's direction has been one-way for months. Bank of America cut to Underperform on October 7, adding to a list that already includes UBS on Sell since April and Scotiabank at Sector Perform since July. The consensus sits at Hold, with eight Hold ratings and one Underperform. No analyst currently carries a Buy. The BofA price target referenced in that downgrade was $3.30 on the US-listed ADR, while ABEV3 closed at BRL 16.25 on the BOVESPA this week. Those are different listing vehicles and should not be compared directly. What is clear from the ratings themselves is that the buy-side has lost conviction. The stock is up 6.4% on the week and 3.2% over the past month, but that recovery has not drawn a single upgrade.
The lending market, however, tells a very different story from the analyst tone. Borrow availability is extraordinarily loose. There are effectively no shares on loan against a deep pool of available stock, with availability running at levels that indicate no meaningful short positioning whatsoever. The ORTEX short score confirms this: at 24.97, it ranks in the 96th percentile for low short activity, meaning fewer stocks in the universe have less short pressure. The cost to borrow data is stale (last updated September 14) but was running at just 1.35% even after a sharp short-term spike from 0.59% in early September. Borrowing has never been expensive here. The gap between analyst caution and actual short positioning is the defining tension on this stock right now.
Factor scores add texture to that gap. Ambev scores in the 94th percentile on dividend quality and ranks at the 100th percentile on days-to-cover, a mechanical consequence of near-zero short interest rather than a squeeze signal. EPS surprise ranks in the 79th percentile, a genuine positive: the company has consistently delivered above estimates. What weighs on the picture is forward earnings growth. The 12-month forward EPS year-on-year growth score ranks in only the 26th percentile, meaning the Street does not see much earnings expansion ahead. The valuation reflects that hesitancy: the P/E multiple has ticked up to 14.9x with the recent price recovery, while EV/EBITDA has nudged above 7.6x.
Ownership is dominated by parent Anheuser-Busch InBev, which holds 63.1% of shares. The next largest disclosed holder is Fundacao Antonio e Helena Zerrenner at 10.4%. Between those two anchors, roughly 73.5% of the company is in hands unlikely to trade. Among the remaining institutional investors, BlackRock added around 5.3 million shares through to September 30, and Wellington Management added 3.8 million through August 31, modest accumulation at the margin. Insider data for ABEV3 is aggregate-level only, with the most recent disclosed trades being routine director activity in August and a Board-level sell of 468,000 shares in late July at BRL 15.65 per share.
The earnings history is thin on reaction data, but the most recent print on July 30 produced a next-day gain of 0.57% followed by a five-day loss of 1.5%, a pattern consistent with a stock where beats are priced in quickly but not sustained. The prior quarter showed a similar fade. With the next print set for October 28, the key question will be whether volume-driven pressure in Brazil and the BRL trajectory have shifted the margin story enough to change any of the eight Hold ratings sitting on the stock.
See the live data behind this article on ORTEX.
Open ABEV3 on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
